A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Imugene Limited
University of Edinburgh
Zhejiang University
AHS Cancer Control Alberta
Epidemiological and Clinical Research Information Network
Jules Bordet Institute
Amgen